Review: Areas of Pediatric Medical Overuse Identified
A recent systematic review identified several established as well as emerging practices utilized in the pediatric setting that were associated with overuse of medical care.
Urologic Disorders
Contepo NDA for Complicated UTI Resubmitted
Fosfomycin is a novel, epoxide intravenous antibiotic with a broad spectrum of Gram-negative and Gram-positive activity, including activity against multi-drug resistant (MDR) strains such as extended spectrum β-lactamase (ESBL)-producing Enterobacteriaceae.
Risk of Acute Kidney Injury With SGLT2 Inhibitors Investigated
Sodium-glucose cotransporter-2 inhibitors (SGLT2is) do not appear to increase the risk of acute kidney injury (AKI), according to the findings of a recently published systematic review and meta-analysis. To evaluate the risk of AKI with these agents, study authors reviewed literature analyzing the effect of SGLT2is on renal adverse events compared with placebo or other…
Itolizumab Receives Fast Track Status for Lupus Nephritis
The FDA has granted Fast Track designation for itolizumab (EQ001; Equillium) for the treatment of lupus nephritis.
Renal Impairment Labeling Updates for Sofosbuvir-Based HCV Therapies
The FDA has approved updated labeling for Epclusa (sofosbuvir/velpatasvir), Harvoni (ledipasvir/sofosbuvir) and Vosevi (sofosbuvir/velpatasvir/voxilaprevir) to include updated information regarding treatment of patients with hepatitis C virus (HCV) who have severe renal impairment including those with end stage renal disease who are on dialysis.
Ultomiris Receives Approval for Atypical Hemolytic Uremic Syndrome
The FDA has approved Ultomiris (ravulizumab-cwvz; Alexion) for the treatment of atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA) in adult and pediatric patients aged 1 month and older.
Diabetes Tx Gains Fast Track Designation for Kidney Disease
The FDA has granted Fast Track designation to dapagliflozin (Farxiga; AstraZeneca) as a possible treatment to delay the progression of renal failure and prevent cardiovascular (CV) and renal death in patients with chronic kidney disease.
Quality of Life Outcomes Comparable Regardless of Treatment With HRT or CRT for Low-Risk Prostate Cancer
Hypofractionated radiotherapy (HRT) offers quality-of-life outcomes similar to conventional radiation therapy for men with low-risk prostate cancer, according to recently published results of a phase 3 randomized study. HRT offers a less expensive and more convenient treatment option for some patients, and in light of the new findings about quality of life, should be considered…
ProVate Gets FDA Approval to Treat Pelvic Organ Prolapse
The FDA has approved ProVate (ConTIPI) for the temporary, nonsurgical management of pelvic organ prolapse in women.
Thiola EC Approved for Treatment of Cystinuria
A new enteric-coated formulation of Thiola has been approved by the Food and Drug Administration for the prevention of cystine stone formation.
- Loading...
Loading...
Next post in Kidney Stones
Loading... 
Loading...